Literature DB >> 16144528

The immunotherapy of prostate and bladder cancer.

Thomas H Totterman1, Angelica Loskog, Magnus Essand.   

Abstract

The role of the immune system in controlling the growth of tumour cells is highly complex and has been extensively debated. It is well documented that the immune system controls virally induced cancers, and there is evidence for a role of specific immunity in other types of tumours. The greater understanding of the regulation and optimization of adoptive, specific immune responses, and the better characterization of tumour-associated antigens indicate the way for active specific vaccination and cell therapy in urological tumours. Currently, bacille Calmette Guerin immunotherapy is established for localized bladder cancer and many experimental immunotherapies are under evaluation. Here we review some timely aspects of tumour immunology, and describe the current status and development of immunotherapy in prostate and bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16144528     DOI: 10.1111/j.1464-410X.2005.05772.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  2 in total

1.  Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas.

Authors:  Helen P Cathro; Mark E Smolkin; Dan Theodorescu; Vickie Y Jo; Soldano Ferrone; Henry F Frierson
Journal:  Cancer Immunol Immunother       Date:  2009-09-16       Impact factor: 6.968

2.  Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.

Authors:  Claire Pieraerts; Virginie Martin; Patrice Jichlinski; Denise Nardelli-Haefliger; Laurent Derre
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.